Brief Title
Development of Diagnostics and Treatment of Urological Cancers
Official Title
Development of Diagnostics and Treatment of Urological Cancers
Brief Summary
The purpose of the study is to evaluate whether state-of-the-art technologies such and next
generation sequencing and drug sensitivity and resistance testing of patient derived tumour
tissue can facilitate research translation and improve outcome of urologic cancers.
Detailed Description
Access to high-quality clinical patient material (e.g. tissue of primary tumor and
metastasis, plasma and urine) linked to comprehensive registry and clinical data and
molecular characterization of the patient material using state-of-the-art technologies (e.g.
NGS, transcriptomics, imaging, DSRT) will facilitate a more rapid translation of basic
research innovations into clinical care (diagnostics, imaging, therapeutics) and result in
improved outcome of patients suffering from urologic cancers ("personalized medicine").
The principal aim of the project is to establish a framework and infrastructure for the
systematic collection and interpretation of biological patient samples. Similarly, the
investigators aim to establish the format how the related clinical and research data can be
made readily accessible for both clinicians and researchers without compromising patient
privacy. The key objectives of the project are to facilitate research translation and to
improve outcome of urologic cancers.
Study Type
Interventional
Primary Outcome
Successful clinical translation
Secondary Outcome
Successful pre-clinical translation
Condition
Prostate Carcinoma
Intervention
Personalised treatment
Study Arms / Comparison Groups
Personalised medicine arm
Description: This is a prospective "n-of-1" type of trial where every patient is his/her own control. This is a study further developing the translational use of an existing framework and infrastructure for systematic sample collection an analytics previously established in the HUB project incorporating NGS and DSRT into clinical care.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Other
Estimated Enrollment
100
Start Date
November 27, 2017
Completion Date
December 2025
Primary Completion Date
December 2025
Eligibility Criteria
Inclusion Criteria:
1. The patient is able to provide written informed consent and is at least 18 years of
age
2. The patient must have a verified diagnosis of an urologic cancer by a board-certified
clinician
Exclusion Criteria:
1. The patient is not willing to provide a written informed consent
2. The patient has a severe psychiatric illness, imprisonment or mental impairment
inflicting on ability to give informed consent
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Antti S Rannikko, MD, PhD, +35894711, [email protected]
Location Countries
Finland
Location Countries
Finland
Administrative Informations
NCT ID
NCT02994758
Organization ID
None yet
Responsible Party
Principal Investigator
Study Sponsor
Helsinki University Central Hospital
Collaborators
Karolinska Institutet
Study Sponsor
Antti S Rannikko, MD, PhD, Principal Investigator, Helsinki University Central Hospital
Verification Date
March 2022